Created at Source Raw Value Validated value
Jan. 5, 2022, 7 a.m. usa

inclusion criteria: participant must be 19 to 49 years of age inclusive, at the time of signing the informed consent. participants who are healthy or medically stabilized according to medical judgment of the investigator based on medical history, physical examination and clinical laboratory tests, etc. participants who are able to attend all scheduled visits and comply with all study procedures. participants who received a primary series of covid-19 vaccination approved for use in korea by mfds and at least 12~24 weeks have passed with no additional covid-19 vaccination. female participants of childbearing potential must agree to be heterosexually inactive, or agree to use at least one acceptable method of contraception from at least 4 weeks prior to the study vaccination (booster vaccination) to 12 weeks after the study vaccination. female participants with a negative urine or serum pregnancy test at screening (however, female participants who are surgically sterile or postmenopausal with amenorrhea for at least 12 months shall be excluded. participants who give signed informed consent which include compliance with the requirements and restrictions listed in the informed consent form and in the protocol.

inclusion criteria: participant must be 19 to 49 years of age inclusive, at the time of signing the informed consent. participants who are healthy or medically stabilized according to medical judgment of the investigator based on medical history, physical examination and clinical laboratory tests, etc. participants who are able to attend all scheduled visits and comply with all study procedures. participants who received a primary series of covid-19 vaccination approved for use in korea by mfds and at least 12~24 weeks have passed with no additional covid-19 vaccination. female participants of childbearing potential must agree to be heterosexually inactive, or agree to use at least one acceptable method of contraception from at least 4 weeks prior to the study vaccination (booster vaccination) to 12 weeks after the study vaccination. female participants with a negative urine or serum pregnancy test at screening (however, female participants who are surgically sterile or postmenopausal with amenorrhea for at least 12 months shall be excluded. participants who give signed informed consent which include compliance with the requirements and restrictions listed in the informed consent form and in the protocol.